ANLOTINIB ORAL MÁS ETOPÓSIDO, CARBOPLATINO y PLACEBO Mejoraron la PFS Frente a ETOPÓSIDO Más CARBOPLATIN y 2 PLACEBOS en ES-SCLC de PRIMERA LÍNEA .
yan Scott .
ANLOTINIB in Combination With ETOPÓSIDE, CARBOPLATIN, and a PLACEBO for BENMELSTOBART (TQB2450) Elicited an Improvement in Progression-Free Survival (PFS) Compared with ETOPÓSIDE and CARBOPLATIN in Combination With PLACEBOS for ANLOTINIB and BENMELSTOBART in The First-Line Treatment of Patients With EXTENSIVE-STAGE SMALL CELL LUNG CÁNCER ( ES-SCLC ), According To Data From The PHASE III ETER701 Trial (NCT04234607) Presented at the 2024 European Lung Cancer Congress .
Findings Showed that in the intent-to-treat (ITT) population, Patients administered ANLOTINIB plus ETOPÓSIDE, CARBOPLATIN and PLACEBO (n = 245) experienced a Median PFS of 5.62 months (95% CI, 5.55-6.83) vs 4.21 months (95% CI, 4.17-4.24) in Patients Treated with ETOPÓSIDE plus CARBOPLATIN and 2 PLACEBOS (n = 247; HR, 0.44; 95% CI, 0.36-0.55; P < .0001) . The 12-month PFS rate was 12.61% (95% CI, 7.81%-18.60%) for the ANLOTINIB arm vs 2.29% (95% CI, 0.56-6.38) for the double PLACEBO arm . ...
.jpg)
.png)
